Avadel Pharmaceuticals (AVDL) Stock Forecast & Price Target

Compare

800 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AVDL Analyst Ratings

Hold

0 Buy

5 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Avadel

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AVDL Stock 12 Month Forecast

Average Price Target

$21.67

▲(0.42% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Avadel Pharmaceuticals in the last 3 months. The average price target is $21.67 with a high forecast of $22.50 and a low forecast of $20.00. The average price target represents a 0.42% change from the last price of $21.58.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","23":"$23","10.25":"$10.25","14.5":"$14.5","18.75":"$18.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$22.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,10.25,14.5,18.75,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.55,21.623076923076923,21.696153846153848,21.76923076923077,21.842307692307692,21.915384615384617,21.98846153846154,22.06153846153846,22.134615384615383,22.20769230769231,22.28076923076923,22.353846153846153,22.426923076923078,{"y":22.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.55,21.55923076923077,21.568461538461538,21.57769230769231,21.586923076923078,21.596153846153847,21.605384615384615,21.614615384615387,21.623846153846156,21.633076923076924,21.642307692307693,21.651538461538465,21.660769230769233,{"y":21.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.55,21.430769230769233,21.31153846153846,21.192307692307693,21.073076923076922,20.953846153846154,20.834615384615386,20.715384615384615,20.596153846153847,20.47692307692308,20.357692307692307,20.23846153846154,20.119230769230768,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.51,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.91,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.51,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.61,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.49,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.81,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.08,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.98,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.89,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.42,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.55,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$22.50

Average Price Target$21.67

Lowest Price Target$20.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Chase Knickerbocker

Craig-Hallum

Hold

―

Assigned

12/18/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Avadel Pharmaceuticals (NASDAQ: AVDL) and Novan (NASDAQ: NOVN)

Benjamin Burnett

Wells Fargo

$22.5

Hold

4.26%

Upside

Reiterated

12/17/25

Wells Fargo Keeps Their Hold Rating on Avadel Pharmaceuticals (AVDL)

Andrew Tsai

Jefferies

$20→$22.5

Hold

4.26%

Upside

Reiterated

11/26/25

Hold Rating on Avadel Pharmaceuticals Amid Acquisition Offer and Market Uncertainties

Ram Selvaraju

H.C. Wainwright

$20

Hold

-7.32%

Downside

Reiterated

11/19/25

Avadel Pharmaceuticals (AVDL) Receives a Hold from H.C. Wainwright

Ami Fadia

Needham

Hold

―

Reiterated

11/05/25

Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (NASDAQ: AVDL) and Sarepta Therapeutics (NASDAQ: SRPT)

Ashwani Verma

UBS

$20

Hold

-7.32%

Downside

Downgraded

10/28/25

Avadel Pharmaceuticals downgraded to Neutral from Buy at UBSAvadel Pharmaceuticals downgraded to Neutral from Buy at UBS

Marc Goodman

Leerink Partners

$22→$18.5

Hold

-14.27%

Downside

Downgraded

10/23/25

Avadel downgraded to Market Perform from Outperform at LeerinkAvadel downgraded to Market Perform from Outperform at Leerink

David Hoang

Deutsche Bank

$18→$20

Hold

-7.32%

Downside

Downgraded

10/23/25

Avadel Pharmaceuticals downgraded to Hold from Buy at Deutsche BankAvadel Pharmaceuticals downgraded to Hold from Buy at Deutsche Bank

David Amsellem

Piper Sandler

$16→$18.5

Hold

-14.27%

Downside

Downgraded

10/22/25

Avadel Pharmaceuticals downgraded to Neutral from Overweight at Piper SandlerAvadel Pharmaceuticals downgraded to Neutral from Overweight at Piper Sandler

Francois Brisebois

LifeSci Capital

Hold

―

Downgraded

10/22/25

Avadel Pharmaceuticals (AVDL) was downgraded to a Hold Rating at LifeSci Capital

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Chase Knickerbocker

Craig-Hallum

Hold

―

Assigned

12/18/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Avadel Pharmaceuticals (NASDAQ: AVDL) and Novan (NASDAQ: NOVN)

Benjamin Burnett

Wells Fargo

$22.5

Hold

4.26%

Upside

Reiterated

12/17/25

Wells Fargo Keeps Their Hold Rating on Avadel Pharmaceuticals (AVDL)

Andrew Tsai

Jefferies

$20→$22.5

Hold

4.26%

Upside

Reiterated

11/26/25

Hold Rating on Avadel Pharmaceuticals Amid Acquisition Offer and Market Uncertainties

Ram Selvaraju

H.C. Wainwright

$20

Hold

-7.32%

Downside

Reiterated

11/19/25

Avadel Pharmaceuticals (AVDL) Receives a Hold from H.C. Wainwright

Ami Fadia

Needham

Hold

―

Reiterated

11/05/25

Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (NASDAQ: AVDL) and Sarepta Therapeutics (NASDAQ: SRPT)

Ashwani Verma

UBS

$20

Hold

-7.32%

Downside

Downgraded

10/28/25

Avadel Pharmaceuticals downgraded to Neutral from Buy at UBSAvadel Pharmaceuticals downgraded to Neutral from Buy at UBS

Marc Goodman

Leerink Partners

$22→$18.5

Hold

-14.27%

Downside

Downgraded

10/23/25

Avadel downgraded to Market Perform from Outperform at LeerinkAvadel downgraded to Market Perform from Outperform at Leerink

David Hoang

Deutsche Bank

$18→$20

Hold

-7.32%

Downside

Downgraded

10/23/25

Avadel Pharmaceuticals downgraded to Hold from Buy at Deutsche BankAvadel Pharmaceuticals downgraded to Hold from Buy at Deutsche Bank

David Amsellem

Piper Sandler

$16→$18.5

Hold

-14.27%

Downside

Downgraded

10/22/25

Avadel Pharmaceuticals downgraded to Neutral from Overweight at Piper SandlerAvadel Pharmaceuticals downgraded to Neutral from Overweight at Piper Sandler

Francois Brisebois

LifeSci Capital

Hold

―

Downgraded

10/22/25

Avadel Pharmaceuticals (AVDL) was downgraded to a Hold Rating at LifeSci Capital

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Avadel Pharmaceuticals

3 Months

xxx

Success Rate

1/2 ratings generated profit

Average Return

+11.25%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +11.25% per trade.

1 Year

PerPlexity Drug Manufacturers - Specialty and GenericTipRanks - PerPlexity

Success Rate

1/2 ratings generated profit

Average Return

+11.25%

reiterated a buy rating 24 days ago

Copying PerPlexity Drug Manufacturers - Specialty and Generic's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +11.25% per trade.

2 Years

xxx

Success Rate

1/2 ratings generated profit

Average Return

+11.25%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +11.25% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AVDL Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AVDL has received 22 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. AVDL average Analyst price target in the past 3 months is 21.67.

Each month's total comprises the sum of three months' worth of ratings.

AVDL Financial Forecast

AVDL Earnings Forecast

Next quarter’s earnings estimate for AVDL is $0.07 with a range of -$0.15 to $0.17. The previous quarter’s EPS was $0.00. AVDL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year AVDL has Performed in-line its overall industry.

AVDL Sales Forecast

Next quarter’s sales forecast for AVDL is $79.45M with a range of $76.58M to $83.00M. The previous quarter’s sales results were $77.47M. AVDL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year AVDL has Performed in-line its overall industry.

AVDL Stock Forecast FAQ

What is AVDL’s average 12-month price target, according to analysts?

Based on analyst ratings, Avadel Pharmaceuticals’s 12-month average price target is 21.67.

What is AVDL’s upside potential, based on the analysts’ average price target?

Avadel Pharmaceuticals has 0.42% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AVDL a Buy, Sell or Hold?

Avadel Pharmaceuticals has a consensus rating of Hold which is based on 0 buy ratings, 5 hold ratings and 0 sell ratings.

What is Avadel Pharmaceuticals’s price target?

The average price target for Avadel Pharmaceuticals is 21.67. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $22.50 ,the lowest forecast is $20.00. The average price target represents 0.42% Increase from the current price of $21.58.

What do analysts say about Avadel Pharmaceuticals?

Avadel Pharmaceuticals’s analyst rating consensus is a Hold. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of AVDL?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Avadel Pharmaceuticals (AVDL) Stock Forecast & Price Target

AVDL Analyst Ratings

AVDL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Avadel Pharmaceuticals

AVDL Analyst Recommendation Trends

AVDL Financial Forecast

AVDL Earnings Forecast

AVDL Sales Forecast

AVDL Stock Forecast FAQ

Detailed List of Analyst Forecasts